

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 28, 2022**

---

**CANDEL THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-40629**  
(Commission  
File Number)

**52-2214851**  
(I.R.S. Employer  
Identification No.)

**Candel Therapeutics, Inc.**  
**117 Kendrick St Suite 450**  
**Needham, Massachusetts 02494**  
(Address of principal executive offices, including zip code)

**(617) 916-5445**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CADL	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022. Following his termination, Estuardo Aguilar-Cordova will remain a member of the Board of Directors. Each of Estuardo Aguilar-Cordova and Laura Aguilar will receive the severance owed to them under their respective employment agreements, filed as Exhibit 10.5.2 and Exhibit 10.5.3, respectively to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 16, 2021, and subject to their execution and non-revocation of a severance and release of claims agreement in favor of the Company.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Candel Therapeutics, Inc.

Date: January 31, 2022

By: /s/ Paul Peter Tak

Paul Peter Tak, M.D., Ph.D., FMedSci  
President and Chief Executive Officer